BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-5960
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma ; volume:6 ; number:1 ; day:15 ; month:3 ; year:2018 ; pages:1-4 ; date:12.2018
Acta Neuropathologica Communications ; 6, Heft 1 (15.3.2018), 1-4, 12.2018
- Creator
- Contributor
-
Camelo-Piragua, Sandra
McFadden, Kathryn
Leung, Denise
Mody, Rajen
Chinnaiyan, Arul
Koschmann, Carl
Venneti, Sriram
SpringerLink (Online service)
- DOI
-
10.1186/s40478-018-0525-1
- URN
-
urn:nbn:de:1111-201805243468
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pratt, Drew
- Camelo-Piragua, Sandra
- McFadden, Kathryn
- Leung, Denise
- Mody, Rajen
- Chinnaiyan, Arul
- Koschmann, Carl
- Venneti, Sriram
- SpringerLink (Online service)
Other Objects (12)
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib
Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib
Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib
Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy